2-HDP清除丙烯醛可保护糖尿病大鼠视网膜神经血管单元完整性
该研究在链脲佐菌素诱导的糖尿病大鼠中评估了丙烯醛清除剂2-HDP对糖尿病视网膜病变神经血管单元功能障碍的影响。2-HDP治疗不影响血糖、体重、饮水量、HbA1c或血压,但减少了视网膜FDP-Lys蓄积,保护了视网膜电图波形、突触蛋白表达和多种视网膜神经元,并减轻了微血管损伤和炎症。人糖尿病视网膜中亦观察到FDP-Lys蓄积,分子动力学模拟提示2-HDP具备全身递送潜力。
要点
- 2-HDP减少糖尿病大鼠视网膜FDP-Lys蓄积并保护神经视网膜功能,不依赖血糖控制。
- 2-HDP减轻视网膜微血管损伤、渗漏和炎症,并维持Müller细胞谷氨酸处理蛋白表达。
- 人2型糖尿病视网膜存在FDP-Lys蓄积,2-HDP具备全身递送潜力,值得进一步研究。
核心结论
- 2-HDP通过减少FDP-Lys蓄积保护糖尿病大鼠视网膜神经血管单元功能,独立于血糖控制。
- 人糖尿病视网膜FDP-Lys蓄积及分子模拟结果支持2-HDP作为糖尿病视网膜病变的潜在治疗药物。
研究设计与样本
- Sprague Dawley大鼠分为非糖尿病组、STZ诱导糖尿病组和STZ诱导糖尿病+饮水给予2-HDP治疗组。
- 终点指标在糖尿病诱导后1至6个月的不同时间点采集,包括ERG、SD-OCT、视网膜血管口径、血压和Evans Blue渗漏等。
- 采用免疫组化评估视网膜神经退行性和血管退行性改变,细胞因子芯片检测视网膜炎症。
- 分析人糖尿病视网膜中FDP-Lys蓄积,并进行计算化学模拟预测2-HDP的被动渗透性和全身递送潜力。
主要发现
- 2-HDP对糖尿病大鼠血糖、体重、饮水量、HbA1c水平和血压无影响(p>0.05)。
- 2-HDP减少视网膜FDP-Lys蓄积(p<0.05),在糖尿病诱导后3和6个月保护ERG波形(暗适应a波、b波和总和振荡电位p<0.05至p<0.001)。
- 2-HDP预防3个月时视网膜变薄(p<0.01),维持内、外丛状层突触素表达(分别p<0.01和p<0.001),并保护视网膜神经节细胞、无长突细胞、双极细胞和光感受器(p<0.05至p<0.01)。
- 2-HDP预防视网膜小动脉扩张(p<0.01),降低微血管通透性(p<0.05),维持周细胞数量并减少无细胞毛细血管形成(p<0.05)。
- 2-HDP抑制小胶质细胞活化(p<0.05),抑制促炎分子上调(p<0.05至p<0.001),并维持Müller细胞谷氨酸天冬氨酸转运体1和谷氨酰胺合成酶表达(p<0.05至p<0.01)。
临床怎么用
- 2-HDP的视网膜保护作用不依赖血糖控制,提示其可能作为糖尿病视网膜病变的辅助治疗靶点。
- 目前证据来自动物模型和体外模拟,尚需进一步临床前和临床研究验证2-HDP在人体中的疗效与安全性。
局限性
- 研究仅在大鼠模型中进行,样本量和具体统计细节未在摘要中报告。
- 人视网膜数据来自死后组织,样本特征和数量未在摘要中说明。
- 2-HDP的全身递送潜力主要基于计算模拟,尚缺乏人体药代动力学数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Diabetic retinal disease (DRD) is characterised by progressive neurovascular unit (NVU) dysfunction, often occurring before visible microvascular damage. Our previous studies suggested that the accumulation of acrolein (ACR)-derived protein adducts on retinal Müller cells and neuronal proteins may contribute to NVU dysfunction in diabetes, although this has yet to be directly tested. In this study, we evaluated the effects of the novel ACR-scavenging drug 2-hydrazino-4,6-dimethylpyrimidine (2-HDP) on retinal NVU dysfunction in experimental diabetes and explored its potential for systemic delivery in humans. METHODS: Sprague Dawley rats were divided into three groups: non-diabetic rats; streptozocin (STZ)-induced diabetic rats; and STZ-induced diabetic rats treated with 2-HDP in their drinking water throughout the duration of diabetes. Endpoint measures were taken at varying time points, ranging from 1 to 6 months post-diabetes induction. Retinal function and structure were evaluated using electroretinography (ERG) and spectral-domain optical coherence tomography (SD-OCT). Retinal vessel calibre, BP and vasopermeability (assessed by Evans Blue leakage) were also monitored. Immunohistochemistry was employed to assess retinal neurodegenerative and vasodegenerative changes, while cytokine arrays were used to investigate the effect of 2-HDP on diabetes-induced retinal inflammation. The accumulation of the ACR-protein adduct Nε-(3-formyl-3,4-dehydropiperidino)lysine (FDP-Lys) in human diabetic retinas was analysed. Computational chemistry simulations were performed to predict 2-HDP's passive permeability properties and its potential for systemic delivery. RESULTS: 2-HDP treatment had no effect on blood glucose, body weight, water intake, HbA1c levels or BP in diabetic rats (p>0.05). However, it protected against retinal FDP-Lys accumulation (p<0.05) and neurophysiological dysfunction, preserving ERG waveforms at 3 and 6 months post-diabetes induction (p<0.05 to p<0.001 for scotopic for a-wave, b-wave and summed oscillatory potentials). SD-OCT imaging revealed that 2-HDP prevented retinal thinning at 3 months (p<0.01) and protected against synaptic dysfunction, as evidenced by preserved synaptophysin expression (p<0.01 and p<0.001 for inner and outer plexiform layers, respectively). It also prevented neurodegeneration by maintaining retinal ganglion cells, amacrine cells, bipolar cells, and photoreceptors (p<0.05 to p<0.01). In addition, 2-HDP prevented retinal arteriolar dilation (p<0.01), reduced microvascular permeability (p<0.05) and attenuated microvascular damage, as indicated by preserved pericyte numbers and reduced acellular capillary formation (p<0.05). Mechanistically, 2-HDP inhibited microglial activation (p<0.05), suppressed the upregulation of proinflammatory molecules associated with NVU dysfunction in the diabetic retina (p<0.05 to p<0.001) and preserved the expression of the Müller cell glutamate-handling proteins, glutamate aspartate transporter 1 and glutamine synthetase (p<0.05 to p<0.01). FDP-Lys accumulation was observed in post-mortem human retinas from individuals with type 2 diabetes (p<0.05), in a pattern that was similar to that in the rat model of diabetes. Molecular dynamics simulations showed that the neutral form of 2-HDP readily crosses cell membranes, with enhanced permeation in the presence of ACR, highlighting its potential for systemic delivery. CONCLUSIONS/INTERPRETATION: 2-HDP protects against retinal NVU dysfunction in diabetic rats by reducing FDP-Lys accumulation, preserving neuroretinal function and preventing microvascular damage, independent of glycaemic control. These results, combined with evidence from human diabetic retinas and molecular dynamics simulations, support 2-HDP's potential as a promising therapeutic agent for DRD, warranting further preclinical and clinical investigation.
引用
- Augustine J, Troendle EP, Friedel T, et al. Scavenging acrolein with 2-HDP preserves neurovascular integrity in a rat model of diabetic retinal disease. Diabetologia. 2025. PMID: 40815371. doi:10.1007/s00125-025-06515-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。